Influence B Blocker Mch Augustus 2008 1
•Download as PPT, PDF•
0 likes•493 views
1) The study examined the influence of continuing or withdrawing beta-blocker therapy on outcomes in patients hospitalized with heart failure. 2) It found that continuing beta-blocker therapy was associated with lower risks while withdrawing therapy was linked to excess mortality. 3) Continuing therapy was also generally well-tolerated according to the results.
Report
Share
Report
Share
Recommended
Beta blockers for heart failure
Beta blockers are the most effective therapy for heart failure according to clinical trials. Long term use of beta blockers such as bisoprolol, carvedilol, and sustained release metoprolol succinate can reduce mortality, heart failure hospitalizations, and improve ejection fraction and symptoms of heart failure. While initiation requires slow uptitration, discontinuation of beta blockers during heart failure hospitalization is generally not necessary and may worsen outcomes.
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blocker
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blockerOnn Akbar Ali MBBS ; FRACP; FCSANZ
Dr. Onn Akbar Ali is a cardiologist who has moved his practice from Australia to Malaysia. He was previously a consultant cardiologist at the Queen Elizabeth and Lyell McEwin Hospitals in Australia. As of August 2013, he has been practicing at the KPJ Kajang Specialist Hospital in Malaysia. The document provides his contact information and updates that he has relocated his practice.Betablocker in chronic stable angina 24-01-2013.
The REACH Registry study found that beta-blockers do not reduce the risk of cardiovascular events like death, heart attack, or stroke in stable outpatients with or without coronary artery disease. However, beta-blockers were found to lower the risk of secondary outcomes in patients who had a heart attack within the past year. The study followed over 45,000 patients for 4 years on average and compared outcomes in patients taking beta-blockers to those not taking them.
The success of neurohormonal blockade: looking back – looking forward: Beta-b...
- The document summarizes the history of beta-blocker treatment for heart failure, from early studies in the 1970s showing potential benefits to large randomized controlled trials in the 1990s and 2000s firmly establishing mortality reduction.
- Key trials included MDC (1993) showing reduced mortality and heart transplantation, CIBIS-II (1999) showing reduced mortality with bisoprolol, MERIT-HF (1999) showing reduced mortality with metoprolol CR/XL, and COPERNICUS (2001) showing reduced mortality, hospitalizations, and worsening heart failure with carvedilol.
- Meta-analyses demonstrated a consistent mortality reduction of approximately 35% associated with beta-blocker use in
Beta blockers in STEMI
Beta blockers have a variety of different uses in the management of ischemic heart disease. This presentation by Dr Vivek Baliga, Internal Medicine Physician talks about the role in ST elevation MI.
Beta Blockers in current cardiovascular practice
betablockers are the drug of choice for prevention of progression of heart failure with mortality benefit, after the evolution of neurohormonal regulation as pathogenesis of heart failure
Betazok in hf_cm_eslides_21jun2010 full slides
This document summarizes the advantages of metoprolol succinate in treating heart failure. It discusses how metoprolol succinate has zero-order kinetics, allowing for once daily dosing. The MERIT-HF trial found that metoprolol succinate reduced total mortality by 34% compared to placebo in heart failure patients. It also reduced sudden death by 41% and death from worsening heart failure by 49%. Metoprolol succinate provides significant clinical benefits for heart failure patients.
The Pharmacology of Beta-Blockers
This document discusses beta-blockers, including their discovery, mechanism of action, uses, side effects, and current research. Beta-blockers were discovered in 1962 and work by blocking beta-1 and beta-2 adrenoceptors. They are used to treat various cardiovascular conditions like hypertension, angina, and arrhythmias. While generally effective, they can cause side effects like bradycardia, bronchospasm, and hypoglycemia. Current research is exploring their potential roles in cancer treatment and fracture prevention.
Recommended
Beta blockers for heart failure
Beta blockers are the most effective therapy for heart failure according to clinical trials. Long term use of beta blockers such as bisoprolol, carvedilol, and sustained release metoprolol succinate can reduce mortality, heart failure hospitalizations, and improve ejection fraction and symptoms of heart failure. While initiation requires slow uptitration, discontinuation of beta blockers during heart failure hospitalization is generally not necessary and may worsen outcomes.
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blocker
Dr. onn akbar ali heart specialist kpj kajang heart failure and beta blockerOnn Akbar Ali MBBS ; FRACP; FCSANZ
Dr. Onn Akbar Ali is a cardiologist who has moved his practice from Australia to Malaysia. He was previously a consultant cardiologist at the Queen Elizabeth and Lyell McEwin Hospitals in Australia. As of August 2013, he has been practicing at the KPJ Kajang Specialist Hospital in Malaysia. The document provides his contact information and updates that he has relocated his practice.Betablocker in chronic stable angina 24-01-2013.
The REACH Registry study found that beta-blockers do not reduce the risk of cardiovascular events like death, heart attack, or stroke in stable outpatients with or without coronary artery disease. However, beta-blockers were found to lower the risk of secondary outcomes in patients who had a heart attack within the past year. The study followed over 45,000 patients for 4 years on average and compared outcomes in patients taking beta-blockers to those not taking them.
The success of neurohormonal blockade: looking back – looking forward: Beta-b...
- The document summarizes the history of beta-blocker treatment for heart failure, from early studies in the 1970s showing potential benefits to large randomized controlled trials in the 1990s and 2000s firmly establishing mortality reduction.
- Key trials included MDC (1993) showing reduced mortality and heart transplantation, CIBIS-II (1999) showing reduced mortality with bisoprolol, MERIT-HF (1999) showing reduced mortality with metoprolol CR/XL, and COPERNICUS (2001) showing reduced mortality, hospitalizations, and worsening heart failure with carvedilol.
- Meta-analyses demonstrated a consistent mortality reduction of approximately 35% associated with beta-blocker use in
Beta blockers in STEMI
Beta blockers have a variety of different uses in the management of ischemic heart disease. This presentation by Dr Vivek Baliga, Internal Medicine Physician talks about the role in ST elevation MI.
Beta Blockers in current cardiovascular practice
betablockers are the drug of choice for prevention of progression of heart failure with mortality benefit, after the evolution of neurohormonal regulation as pathogenesis of heart failure
Betazok in hf_cm_eslides_21jun2010 full slides
This document summarizes the advantages of metoprolol succinate in treating heart failure. It discusses how metoprolol succinate has zero-order kinetics, allowing for once daily dosing. The MERIT-HF trial found that metoprolol succinate reduced total mortality by 34% compared to placebo in heart failure patients. It also reduced sudden death by 41% and death from worsening heart failure by 49%. Metoprolol succinate provides significant clinical benefits for heart failure patients.
The Pharmacology of Beta-Blockers
This document discusses beta-blockers, including their discovery, mechanism of action, uses, side effects, and current research. Beta-blockers were discovered in 1962 and work by blocking beta-1 and beta-2 adrenoceptors. They are used to treat various cardiovascular conditions like hypertension, angina, and arrhythmias. While generally effective, they can cause side effects like bradycardia, bronchospasm, and hypoglycemia. Current research is exploring their potential roles in cancer treatment and fracture prevention.
Beta blocker in acute mi
The document summarizes evidence from randomized controlled trials on the use of beta blockers in patients with acute myocardial infarction (AMI). It discusses several landmark trials from the pre-reperfusion, thrombolysis, and primary PCI eras that demonstrated the benefits of early beta blocker initiation in reducing infarct size, ventricular arrhythmias, cardiogenic shock, and mortality following AMI. The COMMIT trial specifically showed that metoprolol reduces reinfarction rates, arrhythmic death, and cardiogenic shock, especially in higher risk Killip class patients.
Beta blockers in SIHD: Yes, all patients should receive them !
A presentation made by Dr. Akshay Mehta on the topic- Beta blockers in SIHD: yes, all patients should receive them !.
This was presented at the SIHD conference, Mumbai, 2015.
Role of beta blockers in the management of cardiovascular diseases
Beta-blockers play an important role in the management of cardiovascular diseases by reducing sympathetic nervous system activation, balancing myocardial oxygen supply and demand, increasing the threshold for ventricular fibrillation during ischemia, and reducing myocardial oxygen consumption. They are indicated for hypertension, ischemic heart disease, arrhythmias, congestive heart failure, and other conditions. Studies show beta-blockers reduce mortality and cardiovascular events in heart failure and post-myocardial infarction more than other drug classes.
Beta blockers in Acute MI
This document discusses beta blockers for acute myocardial infarction (AMI). It provides an overview of their mechanism of benefit in AMI, indications and recommendations, and evidence supporting their use. The evidence shows beta blockers reduce infarct size, mortality, and arrhythmias when started early after AMI. Intravenous initiation is generally not recommended for fibrinolytic-treated patients, but oral initiation within 24 hours is. Long-term beta blocker therapy for up to 3 years is also indicated to reduce mortality post-AMI.
CARVEDILOL MORE THAN MERE A BETA-BLOCKER
ABSTRACT
Carvedilol is a cardiovascular drug of multifaceted therapeutic potential, with beta-blocker and vasodilatative activity. These actions confer to the above mentioned beta blocker some beneficial properties on several processes involving cardiovascular system. Carvedilol provides hemodynamic, ant ischemic, anti-proliferative and antiarrhytmic benefits, for its antioxidant neuro humoral and electrophysiological effects. All these actions provide the basis for usefulness of the drug in the treatment of hypertension, coronary heart disease, and congestive heart failure. In this review we report the beneficial properties of Carvedilol and we analyze the rational clinical use of this beta blocker taking special attention on recent clinical trial in heart failure where it appears evidence supporting an important, favorable effect of the drug.
KEYWORDS: Carvedilol, Hypertension, Coronary disease, Hearth failure.
Launching Simposium PIT IDI Kota Bogor 2013
1) Beta blockers are commonly used to treat cardiovascular diseases like hypertension and heart failure. They are classified based on selectivity for beta-1 receptors and generation.
2) Beta blockers lower blood pressure and heart rate, reducing myocardial oxygen demand. They protect against arrhythmias and apoptosis. In heart failure, they improve beta receptor signaling and calcium handling.
3) Clinical trials show beta blockers reduce mortality when used for acute treatment, secondary prevention, and in patients with diabetes and coronary artery disease. They are recommended for hypertension in patients with concomitant coronary disease.
Beta blockers in cardiology practice
1) Beta blockers are recommended in current cardiovascular guidelines for the treatment of hypertension and heart failure.
2) Studies have shown that lowering blood pressure, including through the use of beta blockers, reduces complications from diabetes such as heart attacks, strokes, and heart failure.
3) Different beta blockers have varying selectivity for beta-1 receptors in the heart versus beta-2 receptors elsewhere. Some beta blockers also have additional alpha-blocking or vasodilating properties.
Secondary Prevention after ACS - Role of Beta Blockers
Dr. Pramudjo Abdulgani, SpJP, FIHA. 3rd Pekanbaru Cardiology Update, August 25th 2013.
Pangeran Hotel Pekanbaru. Learn more at PerkiPekanbaru.com
Beta blockers in cardiology
Beta-blockers were developed by Sir James Black in the 20th century and are considered one of the most important medical advances. They are commonly used to treat cardiovascular conditions like hypertension, angina, heart failure, and arrhythmias. Beta-blockers work by blocking beta-adrenergic receptors in the heart and vessels. They have various beneficial effects including reducing heart rate, blood pressure, myocardial oxygen demand, and the risk of arrhythmias. Larger clinical trials demonstrated improved outcomes with beta-blockers in conditions like heart attack and heart failure.
Bystolic
Formulary recommendations for an MAPD plan, based on the evaluation of its clinical benefits & possible
place in therapy amongst other beta blockers
Beta adrenergic blocking drugs
This document discusses beta blockers, including their classification, mechanisms of action, uses, and side effects. It notes that beta blockers work by blocking beta-1 and beta-2 adrenergic receptors. They are commonly used to treat hypertension, angina, arrhythmias, and myocardial infarction. Specific drugs like metoprolol, atenolol and carvedilol are mentioned as preferred treatment options depending on the condition. Potential adverse reactions include worsening heart failure, bradycardia, bronchospasm, and metabolic effects.
Htn combination portsaid
Hypertension is often difficult to treat effectively despite available drugs. Combination drug therapy is usually needed to control blood pressure, as monotherapy is only effective in 40-60% of patients. Using two drugs with different mechanisms of action can more effectively lower blood pressure than monotherapy alone. Common effective combinations include a diuretic paired with a renin-angiotensin system inhibitor, calcium channel blocker, or beta blocker. This helps control blood pressure through multiple pathways and limits side effects.
Beta adrenergic blockers
This presentation deals with the beta blockers commonly used in day-to-day practice alongwith some interesting mnemonics to remember their names & site of action
beta blockers
Natural Sources of Drugs e.g. from Microorganisms Prepared by Mustafa Kamal Ahmed Khan, Jamia Hamdard, New Delhi.
Betaadrenergicblockers 150412052808-conversion-gate01
Beta adrenergic blockers (β-blockers) are a class of drugs that are competitive antagonists of beta-adrenergic receptors. They are used to treat hypertension, ischemic heart disease, cardiac arrhythmias, heart failure, glaucoma, and other conditions. β-blockers are classified as non-selective or cardioselective. Non-selective β-blockers block β1 and β2 receptors, while cardioselective β-blockers selectively block β1 receptors in the heart. β-blockers produce their effects by inhibiting the sympathetic nervous system's stimulation of the heart and circulation. They reduce heart rate, blood pressure, and cardiac contractility, thereby reducing myocardial oxygen demand.
Carvedilol in the management of mi and heart failure
This document summarizes clinical studies comparing the effects of carvedilol and metoprolol in patients with myocardial infarction (MI) and heart failure (HF). Several studies found that carvedilol improved outcomes more than metoprolol, reducing mortality, improving quality of life, and decreasing hospital readmissions in post-MI and HF patients. Carvedilol's multi-receptor blocking properties allow it to provide better sympatholytic effects than metoprolol. The document concludes that carvedilol is a better choice than metoprolol for treating patients with MI or HF.
Pharmacotherapy in HFrEF
This document discusses pharmacological management options for heart failure with reduced ejection fraction (HFrEF). The goals of treatment are to reduce symptoms, prolong survival, improve quality of life, and prevent disease progression. Key drug therapies recommended for prognosis include ACE inhibitors, ARBs, beta blockers, and mineralocorticoid receptor antagonists. Diuretics and digoxin are recommended to treat symptoms. Ivabradine may also be used for symptom control. Clinical trials have demonstrated the benefits of these drug classes in reducing mortality and hospitalizations.
Perioperative Beta Blockers in non-cardiac surgery and POISE
Review of the evidence that supported the use of Beta-blockers in the peri-operative setting and the data from the POISE trial.
Telmisartan combination uses
1. The document discusses guidelines and strategies for the prevention, treatment, and control of hypertension.
2. It outlines 4 stages of intervention for hypertension: preventive, primary, secondary, and resistant hypertension. Treatment approaches differ depending on the stage.
3. The challenges of controlling hypertension include special patient populations, factors influencing drug choice, and issues related to resistant hypertension when blood pressure remains high despite treatment with 3 drug classes.
Nebil
This document discusses hypertension, also known as the "Dajal of the 21st century". It provides an overview of cardiovascular risks associated with increases in blood pressure. It then discusses approaches for managing hypertension, including lifestyle modifications and medical therapy. Specific antihypertensive drugs discussed include ACE inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, and thiazide diuretics. Nebivolol, a beta blocker with nitric oxide mediated vasodilation properties, is highlighted for its ability to improve endothelial function compared to other beta blockers.
ADRENERGIC BLOCKERS
This presentation contains drugs which blocks the adrenergic system e.g receptor blockers like alpha and beta receptor antagonists, adrenergic neuron blocking agents in details.various animated pictures are also included to make the presentation interesting as well as i have used various diagrams and tables to have better understanding of the topic. Thank you.
Beta blockers
Beta blockers are a class of drugs that are used to treat high blood pressure and heart conditions by blocking beta-adrenergic receptors. There are several types of beta blockers that are categorized based on their selectivity and other properties. Some are cardioselective, meaning they mainly affect the heart, while others are non-selective. Beta blockers have various therapeutic uses for conditions like hypertension, angina, arrhythmias, and migraine prevention. Their effects are primarily cardiovascular in nature by slowing the heart rate and reducing blood pressure. Common adverse effects include worsening heart failure and bronchospasm.
More Related Content
What's hot
Beta blocker in acute mi
The document summarizes evidence from randomized controlled trials on the use of beta blockers in patients with acute myocardial infarction (AMI). It discusses several landmark trials from the pre-reperfusion, thrombolysis, and primary PCI eras that demonstrated the benefits of early beta blocker initiation in reducing infarct size, ventricular arrhythmias, cardiogenic shock, and mortality following AMI. The COMMIT trial specifically showed that metoprolol reduces reinfarction rates, arrhythmic death, and cardiogenic shock, especially in higher risk Killip class patients.
Beta blockers in SIHD: Yes, all patients should receive them !
A presentation made by Dr. Akshay Mehta on the topic- Beta blockers in SIHD: yes, all patients should receive them !.
This was presented at the SIHD conference, Mumbai, 2015.
Role of beta blockers in the management of cardiovascular diseases
Beta-blockers play an important role in the management of cardiovascular diseases by reducing sympathetic nervous system activation, balancing myocardial oxygen supply and demand, increasing the threshold for ventricular fibrillation during ischemia, and reducing myocardial oxygen consumption. They are indicated for hypertension, ischemic heart disease, arrhythmias, congestive heart failure, and other conditions. Studies show beta-blockers reduce mortality and cardiovascular events in heart failure and post-myocardial infarction more than other drug classes.
Beta blockers in Acute MI
This document discusses beta blockers for acute myocardial infarction (AMI). It provides an overview of their mechanism of benefit in AMI, indications and recommendations, and evidence supporting their use. The evidence shows beta blockers reduce infarct size, mortality, and arrhythmias when started early after AMI. Intravenous initiation is generally not recommended for fibrinolytic-treated patients, but oral initiation within 24 hours is. Long-term beta blocker therapy for up to 3 years is also indicated to reduce mortality post-AMI.
CARVEDILOL MORE THAN MERE A BETA-BLOCKER
ABSTRACT
Carvedilol is a cardiovascular drug of multifaceted therapeutic potential, with beta-blocker and vasodilatative activity. These actions confer to the above mentioned beta blocker some beneficial properties on several processes involving cardiovascular system. Carvedilol provides hemodynamic, ant ischemic, anti-proliferative and antiarrhytmic benefits, for its antioxidant neuro humoral and electrophysiological effects. All these actions provide the basis for usefulness of the drug in the treatment of hypertension, coronary heart disease, and congestive heart failure. In this review we report the beneficial properties of Carvedilol and we analyze the rational clinical use of this beta blocker taking special attention on recent clinical trial in heart failure where it appears evidence supporting an important, favorable effect of the drug.
KEYWORDS: Carvedilol, Hypertension, Coronary disease, Hearth failure.
Launching Simposium PIT IDI Kota Bogor 2013
1) Beta blockers are commonly used to treat cardiovascular diseases like hypertension and heart failure. They are classified based on selectivity for beta-1 receptors and generation.
2) Beta blockers lower blood pressure and heart rate, reducing myocardial oxygen demand. They protect against arrhythmias and apoptosis. In heart failure, they improve beta receptor signaling and calcium handling.
3) Clinical trials show beta blockers reduce mortality when used for acute treatment, secondary prevention, and in patients with diabetes and coronary artery disease. They are recommended for hypertension in patients with concomitant coronary disease.
Beta blockers in cardiology practice
1) Beta blockers are recommended in current cardiovascular guidelines for the treatment of hypertension and heart failure.
2) Studies have shown that lowering blood pressure, including through the use of beta blockers, reduces complications from diabetes such as heart attacks, strokes, and heart failure.
3) Different beta blockers have varying selectivity for beta-1 receptors in the heart versus beta-2 receptors elsewhere. Some beta blockers also have additional alpha-blocking or vasodilating properties.
Secondary Prevention after ACS - Role of Beta Blockers
Dr. Pramudjo Abdulgani, SpJP, FIHA. 3rd Pekanbaru Cardiology Update, August 25th 2013.
Pangeran Hotel Pekanbaru. Learn more at PerkiPekanbaru.com
Beta blockers in cardiology
Beta-blockers were developed by Sir James Black in the 20th century and are considered one of the most important medical advances. They are commonly used to treat cardiovascular conditions like hypertension, angina, heart failure, and arrhythmias. Beta-blockers work by blocking beta-adrenergic receptors in the heart and vessels. They have various beneficial effects including reducing heart rate, blood pressure, myocardial oxygen demand, and the risk of arrhythmias. Larger clinical trials demonstrated improved outcomes with beta-blockers in conditions like heart attack and heart failure.
Bystolic
Formulary recommendations for an MAPD plan, based on the evaluation of its clinical benefits & possible
place in therapy amongst other beta blockers
Beta adrenergic blocking drugs
This document discusses beta blockers, including their classification, mechanisms of action, uses, and side effects. It notes that beta blockers work by blocking beta-1 and beta-2 adrenergic receptors. They are commonly used to treat hypertension, angina, arrhythmias, and myocardial infarction. Specific drugs like metoprolol, atenolol and carvedilol are mentioned as preferred treatment options depending on the condition. Potential adverse reactions include worsening heart failure, bradycardia, bronchospasm, and metabolic effects.
Htn combination portsaid
Hypertension is often difficult to treat effectively despite available drugs. Combination drug therapy is usually needed to control blood pressure, as monotherapy is only effective in 40-60% of patients. Using two drugs with different mechanisms of action can more effectively lower blood pressure than monotherapy alone. Common effective combinations include a diuretic paired with a renin-angiotensin system inhibitor, calcium channel blocker, or beta blocker. This helps control blood pressure through multiple pathways and limits side effects.
Beta adrenergic blockers
This presentation deals with the beta blockers commonly used in day-to-day practice alongwith some interesting mnemonics to remember their names & site of action
beta blockers
Natural Sources of Drugs e.g. from Microorganisms Prepared by Mustafa Kamal Ahmed Khan, Jamia Hamdard, New Delhi.
Betaadrenergicblockers 150412052808-conversion-gate01
Beta adrenergic blockers (β-blockers) are a class of drugs that are competitive antagonists of beta-adrenergic receptors. They are used to treat hypertension, ischemic heart disease, cardiac arrhythmias, heart failure, glaucoma, and other conditions. β-blockers are classified as non-selective or cardioselective. Non-selective β-blockers block β1 and β2 receptors, while cardioselective β-blockers selectively block β1 receptors in the heart. β-blockers produce their effects by inhibiting the sympathetic nervous system's stimulation of the heart and circulation. They reduce heart rate, blood pressure, and cardiac contractility, thereby reducing myocardial oxygen demand.
Carvedilol in the management of mi and heart failure
This document summarizes clinical studies comparing the effects of carvedilol and metoprolol in patients with myocardial infarction (MI) and heart failure (HF). Several studies found that carvedilol improved outcomes more than metoprolol, reducing mortality, improving quality of life, and decreasing hospital readmissions in post-MI and HF patients. Carvedilol's multi-receptor blocking properties allow it to provide better sympatholytic effects than metoprolol. The document concludes that carvedilol is a better choice than metoprolol for treating patients with MI or HF.
Pharmacotherapy in HFrEF
This document discusses pharmacological management options for heart failure with reduced ejection fraction (HFrEF). The goals of treatment are to reduce symptoms, prolong survival, improve quality of life, and prevent disease progression. Key drug therapies recommended for prognosis include ACE inhibitors, ARBs, beta blockers, and mineralocorticoid receptor antagonists. Diuretics and digoxin are recommended to treat symptoms. Ivabradine may also be used for symptom control. Clinical trials have demonstrated the benefits of these drug classes in reducing mortality and hospitalizations.
Perioperative Beta Blockers in non-cardiac surgery and POISE
Review of the evidence that supported the use of Beta-blockers in the peri-operative setting and the data from the POISE trial.
Telmisartan combination uses
1. The document discusses guidelines and strategies for the prevention, treatment, and control of hypertension.
2. It outlines 4 stages of intervention for hypertension: preventive, primary, secondary, and resistant hypertension. Treatment approaches differ depending on the stage.
3. The challenges of controlling hypertension include special patient populations, factors influencing drug choice, and issues related to resistant hypertension when blood pressure remains high despite treatment with 3 drug classes.
Nebil
This document discusses hypertension, also known as the "Dajal of the 21st century". It provides an overview of cardiovascular risks associated with increases in blood pressure. It then discusses approaches for managing hypertension, including lifestyle modifications and medical therapy. Specific antihypertensive drugs discussed include ACE inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, and thiazide diuretics. Nebivolol, a beta blocker with nitric oxide mediated vasodilation properties, is highlighted for its ability to improve endothelial function compared to other beta blockers.
What's hot (20)
Beta blockers in SIHD: Yes, all patients should receive them !
Beta blockers in SIHD: Yes, all patients should receive them !
Role of beta blockers in the management of cardiovascular diseases
Role of beta blockers in the management of cardiovascular diseases
Secondary Prevention after ACS - Role of Beta Blockers
Secondary Prevention after ACS - Role of Beta Blockers
Betaadrenergicblockers 150412052808-conversion-gate01
Betaadrenergicblockers 150412052808-conversion-gate01
Carvedilol in the management of mi and heart failure
Carvedilol in the management of mi and heart failure
Perioperative Beta Blockers in non-cardiac surgery and POISE
Perioperative Beta Blockers in non-cardiac surgery and POISE
Viewers also liked
ADRENERGIC BLOCKERS
This presentation contains drugs which blocks the adrenergic system e.g receptor blockers like alpha and beta receptor antagonists, adrenergic neuron blocking agents in details.various animated pictures are also included to make the presentation interesting as well as i have used various diagrams and tables to have better understanding of the topic. Thank you.
Beta blockers
Beta blockers are a class of drugs that are used to treat high blood pressure and heart conditions by blocking beta-adrenergic receptors. There are several types of beta blockers that are categorized based on their selectivity and other properties. Some are cardioselective, meaning they mainly affect the heart, while others are non-selective. Beta blockers have various therapeutic uses for conditions like hypertension, angina, arrhythmias, and migraine prevention. Their effects are primarily cardiovascular in nature by slowing the heart rate and reducing blood pressure. Common adverse effects include worsening heart failure and bronchospasm.
Beta blockers
Beta blockers act on beta 1 and/or beta 2 receptors. They are classified as non-selective, selective, and mixed blockers. Non-selective blockers like propranolol block both beta 1 and beta 2 receptors. They are used for cardiovascular conditions like hypertension, angina, heart failure, and arrhythmias. Adverse effects include bronchospasm, bradycardia, hypoglycemia, and heart failure. Cardioselective blockers mainly block beta 1 receptors. Newer blockers have improved safety profiles.
Beta blockers
Beta receptor blockers are a class of drugs that are commonly used to treat cardiovascular conditions by blocking beta-1 and beta-2 receptors. They have several therapeutic uses including hypertension, congestive heart failure, angina, myocardial infarction, and cardiac arrhythmias. They work by decreasing heart rate, contractility, and blood pressure. Common side effects include fatigue, bronchospasm, and metabolic abnormalities. First generation blockers are non-selective while later generations are more cardioselective. Carvedilol is used for heart failure, atenolol for hypertension, and esmolol for emergencies. Propranolol is effective for migraine prevention. Timolol eye drops are used for glaucoma treatment by decreasing
Alpha adrenergic blockers
This document summarizes the classification, mechanisms of action, pharmacokinetics, and clinical uses of α-adrenergic receptor antagonists (α-blockers). It discusses non-selective α-blockers that block both α1 and α2 receptors like phentolamine and phenoxybenzamine, as well as selective α1-blockers like prazosin, doxazosin, tamsulosin, and selective α2-blockers like yohimbine. The major uses of α-blockers include treatment of pheochromocytoma, hypertension, peripheral vascular disease, benign prostatic hyperplasia, migraine, and congestive heart failure. Common side effects include hypotension
Journal Reading HF-Action Trial 2012
This study examined the relationship between beta-blocker (BB) dose and clinical outcomes in patients with heart failure using data from the HF-ACTION trial. The study found that higher BB dose was associated with a lower risk of the primary composite outcome of all-cause death or hospitalization. Higher doses were also linked to longer exercise duration and higher peak oxygen consumption. Additionally, higher doses did not increase the risk of bradycardia or other cardiovascular events. The results support guideline recommendations to titrate BB therapy to moderate-to-high doses used in clinical trials for better clinical outcomes in heart failure patients.
ACES: CV Drugs / Pesticides
This document discusses various topics related to cardiovascular drug toxicity, including:
1) Digoxin toxicity and its treatment with DigiFab fragments. Digoxin toxicity can cause various arrhythmias and the EKG may show conduction blocks.
2) Beta-blocker overdose treatment involves glucagon, insulin, and other inotropic support. High-dose insulin increases cardiac output by improving stroke volume rather than heart rate.
3) The EKG shows bidirectional ventricular tachycardia, a specific finding for digoxin toxicity. Intravenous lipid emulsion acts as a "sink" for lipid-soluble beta blockers and should be considered as a salvage treatment in massive overdoses.
Support Tools für die Admin-Konsole - Nebil Kisa, Advanced Support Engineer
Alfresco Day München 2016 - 14. Juni 2016 - #AlfrescoDayMunich - https://www.alfresco.com/de/veranstaltungen/alfresco-day-munchen-2016
Beta blockers in sihd
Dr. Amit Vora discusses the use of beta-blockers in certain patient populations. While beta-blockers are clearly beneficial for up to 3 years in post-MI patients and for those with LV ejection fraction below 0.40, their use in other groups is less certain. Specifically, a study found beta-blockers given at discharge to stable angina patients without prior MI or HF undergoing elective PCI did not decrease mortality, revascularization or rehospitalization. Additionally, beta-blockers have potential adverse effects and may fail to provide benefits given current standard therapies. Their use should be limited to post-MI patients and those with CHF and reduced LVEF.
B blockers
This document summarizes beta blockers, including their mechanism of action, classification, properties, uses, adverse effects and drug interactions. Beta blockers work by blocking beta receptors and inhibiting the adrenergic response. They are classified as first, second or third generation, and can be selective for beta 1 receptors or non-selective. Common uses include hypertension, angina, arrhythmias, migraine prophylaxis and anxiety. Side effects include bradycardia, bronchospasm and hypoglycemia. Drug interactions can occur pharmacokinetically or pharmacodynamically with drugs like digoxin. Overdose treatment involves atropine, pacing and glucagon administration.
03 Adrenergic Blockers Upd
This document summarizes adrenergic agents and adrenergic-blocking agents. It describes how adrenergic agents mimic the effects of the sympathetic nervous system by stimulating alpha-adrenergic and beta-adrenergic receptors located throughout the body. It also describes how adrenergic-blocking agents, also called sympatholytics, inhibit the effects of the sympathetic nervous system by blocking these same receptors. Examples of different types of adrenergic and adrenergic-blocking agents are provided along with their therapeutic uses and important monitoring parameters.
Assessment of mitral valve for PTMC
Mitral valve morphology assessed via echocardiography is the strongest predictor of outcomes for percutaneous mitral balloon dilation (PTMC). A combined echocardiographic scoring system that includes assessment of leaflet thickness, calcification, mobility and subvalvular thickening can help identify patients likely to have optimal versus suboptimal results. A total score above 11 generally indicates PTMC will be suboptimal, while a score below 9 suggests an optimal outcome. Pre-procedural transesophageal echocardiography is also important to rule out left atrial thrombus, especially in patients with atrial fibrillation. Careful patient selection based on echocardiographic scoring and screening for thrombus can help maximize benefits and
Heartfailure
1. The 2012 Focused Update provides updated guidelines for the diagnosis and management of heart failure in adults.
2. It emphasizes the progressive nature of left ventricular dysfunction and stages of heart failure from risk to end-stage disease.
3. New mechanisms and models of heart failure are discussed, including the cardiorenal model, hemodynamic model, and neurohormonal hypothesis.
2009 ACCF/AHA Heart Failure Guidelines
2009 Focused Update:
ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults
J. Am. Coll. Cardiol. April 14, 2009; 53;1343-1382
Circulation. April 14, 2009;119;1977-2016
Beta blockers in hypertension
1. Beta-blockers are not recommended as initial treatment for uncomplicated hypertension but may be beneficial for conditions like angina, heart failure, and recent myocardial infarction.
2. Studies have shown that beta-blockers are less effective at reducing central aortic pressure compared to other drug classes, which may explain their reduced ability to protect against stroke.
3. While beta-blockers reduce mortality when used for approved indications like heart failure, their long-term benefits after myocardial infarction are unclear as studies have shown no additional survival benefit with long-term adherence compared to discontinuation after one year.
Sujay iyer beta blockers
This document discusses the role of beta blockers in the treatment of hypertension. It covers the pharmacodynamics and pharmacokinetics of beta blockers, specific agents used, their adverse effects, history of use, and concerns regarding their use based on clinical trial data. It indicates that beta blockers are still indicated for hypertension when used selectively in patients with conditions like diabetes or coronary artery disease, and that newer vasodilating beta blockers may provide benefits over older non-selective agents.
Bisoprolol
This document discusses bisoprolol, a beta-1 selective adrenoceptor blocking agent used to treat hypertension and angina. It provides details on bisoprolol's history, pharmacological properties, therapeutic indications, contraindications, adverse reactions, and toxicological studies. Bisoprolol is a highly selective beta-1 blocker that is well-absorbed orally and has a half-life of 10-12 hours. It is used to treat hypertension, angina, and heart failure by reducing heart rate and contractility. Adverse effects include fatigue, dizziness, and bronchospasm. Toxicology studies found it to be non-cytotoxic, non-mutagenic, and
Cardiology Board Review 2008
1. The document discusses treatment guidelines for a 55-year-old male presenting with chest pain, including administering aspirin, heparin, beta blockers, and transferring the patient for primary angioplasty within 90 minutes.
2. It provides an overview of guidelines for various treatments of acute coronary syndromes, including thrombolytics, primary PCI, facilitated PCI, and rescue PCI.
3. The document reviews evidence and recommendations for therapies like beta blockers, analgesics, and anticoagulants in treating acute coronary syndromes.
Pharmacotherapy in Chronical Systolic Heart Failure
This document discusses pharmacological treatment for chronic systolic heart failure. It outlines the goals of treatment as relieving symptoms and preventing hospitalization and death. It provides recommendations from guidelines for evidence-based medications including ACE inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and others. It notes demonstration of benefits from randomized clinical trials including relative risk reductions in mortality from different drug classes.
Beta blockers
Beta-blockers were developed by Sir James Black and are considered one of the most important medical advances of the 20th century. Sir James Black received the Nobel Prize in 1988 for his work developing beta-blockers. Beta-blockers are used to treat numerous cardiovascular conditions including hypertension, angina, heart failure, and cardiac arrhythmias. They work by blocking beta-adrenergic receptors to reduce heart rate, blood pressure, and myocardial oxygen demand. Long-term use of beta-blockers has been shown to improve outcomes for patients with heart disease.
Viewers also liked (20)
Support Tools für die Admin-Konsole - Nebil Kisa, Advanced Support Engineer
Support Tools für die Admin-Konsole - Nebil Kisa, Advanced Support Engineer
Pharmacotherapy in Chronical Systolic Heart Failure
Pharmacotherapy in Chronical Systolic Heart Failure
Similar to Influence B Blocker Mch Augustus 2008 1
Intensive Insulin Therapy In The Medical Icu
Intensive insulin therapy (IIT) aimed at maintaining tight glycemic control between 4.4-6.1 mmol/L significantly reduced morbidity but not overall in-hospital mortality compared to conventional insulin treatment targeting levels below 10-12 mmol/L in critically ill adult medical ICU patients. Among patients who received at least 3 days of IIT, in-hospital mortality was reduced from 21% to 14% and complications such as newly acquired kidney injury and length of stay were also lower. However, IIT did not reduce mortality in the overall intention-to-treat analysis and may have caused harm in patients treated for less than 3 days. Further research is needed to confirm these preliminary findings.
The New Standard of Care__Leveraging the Benefits of SGLT2 Inhibitors Across ...
This document provides information about an upcoming conference session on leveraging the benefits of SGLT2 inhibitors across the heart failure spectrum. The session will take place on October 8, 2023 in Cleveland, Ohio and feature two faculty members who will provide presentations and disclose any relevant financial relationships. The learning objectives are to discuss the latest evidence supporting SGLT2 inhibitors as treatments for patients with heart failure, across different classifications based on ejection fraction. Recent guideline updates are highlighted, emphasizing a new staging system for heart failure and recommending SGLT2 inhibitors for all stages of heart failure.
AFFIRM trial JC NOVANT
The AFFIRM trial compared rate control and rhythm control strategies for treating atrial fibrillation. Over 7,000 patients with recurrent atrial fibrillation aged 65 or older were randomized to either rate or rhythm control. The primary outcome was overall mortality, with secondary outcomes including death from cardiovascular causes, stroke, bleeding, and hospitalization. The trial found no significant difference in mortality between the two groups. However, rhythm control was associated with greater need for hospitalization and higher rates of crossover to rate control. The study concluded that rate control should be the primary treatment approach for atrial fibrillation.
Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..
1) A study evaluated the addition of ivabradine to metoprolol in patients with stable angina pectoris and found that it significantly reduced mean resting heart rate, weekly angina attacks, and use of short-acting nitrates over 4 months compared to baseline.
2) The mean heart rate fell by 19.7 bpm, weekly angina attacks decreased 8-fold, and quality of life scores increased with the combination therapy.
3) Heart rate reductions and clinical benefits were greater in patients who had higher baseline heart rates of 70 bpm or more.
HIV Alert- Options for Integrase Inhibitor Therapy Following Recent Drug Appr...
In this downloadable slideset, Paul E. Sax, MD, and Brian R. Wood, MD, provide expert insight into the use of recently-approved INSTI regimens and discuss how these regimens fit into the current HIV treatment landscape.
Format: Microsoft PowerPoint (.ppt)
File size: 331 KB
Date posted: 3/6/2018
Download
Bd1e Management Of Heart Failure
This document summarizes guidelines for managing chronic heart failure. It discusses evaluating patients, lifestyle modifications including diet and exercise, and pharmacological treatments. Key drugs discussed are ACE inhibitors, ARBs, beta blockers, aldosterone antagonists, and digoxin. Several clinical trials are summarized that demonstrate the mortality benefits of these drug classes in heart failure.
Trattamento antivirale e controllo della malattia: benefici a lungo termine
- Long-term treatment of chronic hepatitis B virus (HBV) infection with antiviral therapy provides clinical benefits including control of symptoms, normalization of liver enzymes, reduction of liver inflammation and fibrosis, and decreased portal hypertension (Long-term benefits).
- Recent data presented at the European Association for the Study of the Liver (EASL) conference in 2014 showed successful long-term viral suppression with tenofovir and entecavir in HBV patients, including those with comorbidities. Combination therapy with pegylated interferon may help reduce HBsAg levels but the optimal regimen requires further study (News from EASL).
- Future treatment strategies aim to achieve a functional cure by reducing
Ezekowitz Explore
The document summarizes a phase 2 clinical trial studying the safety and efficacy of the oral factor Xa inhibitor betrixaban compared to warfarin in patients with non-valvular atrial fibrillation. The trial found that major or clinically relevant non-major bleeding was comparable between betrixaban doses of 60-80mg and warfarin. Stroke rates were also similar. Betrixaban was well-tolerated across doses with dose-dependent increases in anti-Xa activity. Larger studies are still needed to fully determine betrixaban's efficacy and safety profile.
Acute Heart Failure
The document summarizes key information about acute heart failure, including epidemiology, pathophysiology, treatment approaches, and trial data. It describes the ASCEND-HF trial which investigated the effects of nesiritide vs placebo on outcomes in over 7,000 patients hospitalized for acute decompensated heart failure. The trial found no significant differences between nesiritide and placebo for its co-primary endpoints of 30-day mortality or heart failure rehospitalization and dyspnea relief at 6 and 24 hours.
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HIV-Infected Patients.2018
In this slideset, Babafemi Taiwo, MBBS, discusses expert approaches to selecting an HIV switch regimen in a series of cases studies involving HIV-infected patients with virologic suppression on their current ART regimen.
Format: Microsoft PowerPoint (.ppt)
File Size: 1.10 MB
Evidence Based Review CHF
The document provides an overview of congestive heart failure (CHF), including its pathophysiology, diagnosis, classification, and treatment recommendations. It discusses how CHF results from neurohumoral and remodeling processes in the heart. Successful treatment requires addressing the sympathetic nervous system and renin-angiotensin-aldosterone system. Evidence shows that ACE inhibitors, beta-blockers, ARBs, and diuretics can improve outcomes when used appropriately based on the patient's stage of CHF.
journal club- dual-antiplatelets therapy Post AMI
This study evaluated the efficacy and safety of adding ticagrelor to low-dose aspirin in stable patients with a history of myocardial infarction. Over 18,000 patients were randomly assigned to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo twice daily in addition to standard medical therapy including aspirin. The primary outcome was a composite of cardiovascular death, myocardial infarction, and stroke. The results showed that ticagrelor at either dose reduced the risk of the primary outcome compared to placebo by 16-19% with no significant difference between the two ticagrelor doses. Ticagrelor increased the risk of TIMI major bleeding but not fatal bleeding or intracere
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
1) Initiating all four guideline directed medical therapies (GDMT) simultaneously or in rapid sequence for heart failure with reduced ejection fraction (HFrEF) provides early clinical benefits by reducing mortality and hospitalization within weeks.
2) Starting medications together enables better tolerance as therapies help patients tolerate side effects of each other. Delaying any medication needlessly increases risks.
3) There is no evidence that simultaneous initiation increases intolerance, and initiating at low doses with up-titration mitigates risks. Not starting medications exposes patients to worsening health outcomes.
Medication non-adherence is associated with a broad range of adverse outcomes...
Presented by:
P. Michael Ho, MD, PhD, David J. Magid, MD, MPH, Susan M. Shetterly, MS, Kari L. Olson, PharmD, BCPS, Thomas M. Maddox, MD, MSc, Pamela N. Peterson, MD, MSPH, Frederick A. Masoudi, MD, MSPH, John S. Rumsfeld, MD, PhD
Packer Cabana
The document summarizes the results of the CABANA Pilot Study, which compared catheter ablation to antiarrhythmic drug therapy for atrial fibrillation. The study found that ablation was more effective than drugs at preventing recurrent symptomatic atrial fibrillation over 12 months of follow-up. However, the pilot study had some limitations due to its small sample size and short follow-up duration. It established the feasibility of conducting a larger pivotal trial to determine long-term outcomes of ablation versus drug therapy for atrial fibrillation.
CABANA
The document summarizes the results of the CABANA Pilot Study, which compared catheter ablation to antiarrhythmic drug therapy for atrial fibrillation. The study found that ablation was more effective than drugs at preventing recurrent symptomatic atrial fibrillation over 12 months of follow-up. However, the pilot study had some limitations due to its small sample size and short follow-up duration. It established the feasibility of conducting a larger pivotal trial to determine long-term outcomes of ablation versus drug therapy for atrial fibrillation.
HIV Alert:Emerging Updates on Dual Therapy.2018
In this downloadable slideset, Joseph J. Eron, Jr., MD, and Babafemi Taiwo, MBBS, provide expert insight into the use of a recently-approved dual-therapy regimen and review data surrounding investigational two-drug regimens.
Format: Microsoft PowerPoint (.ppt)
File size: 375 KB
Date posted: 1/5/2018
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
This document discusses managing chronic heart failure (CHF) with beta blockers in the era of angiotensin receptor-neprilysin inhibitors (ARNI). It begins by outlining the global prevalence and mortality rates of heart failure, which remain high. It then reviews the mechanisms of benefit of beta blockers in CHF, noting they lower heart rate and mortality risk by blocking sympathetic nervous system overactivation. The document evaluates the efficacy and side effect profiles of various beta blockers, finding bisoprolol to have the lowest rates of adverse events like sexual dysfunction. It concludes by presenting updated treatment algorithms for CHF that incorporate both beta blockers and novel therapies like ARNI, noting ARNI can potentially cause
Escape
The ESCAPE trial was a randomized controlled trial investigating whether intensified blood pressure control aimed at achieving low-normal 24-hour blood pressure levels could slow the progression of chronic kidney disease in children receiving ACE inhibitor therapy. The trial found that intensified blood pressure control reduced the risk of kidney function decline or end-stage renal disease by 35% over 5 years compared to conventional blood pressure control. Additional benefits included reduced proteinuria levels initially and lower blood pressure overall. However, proteinuria increased again over time, suggesting potential aldosterone breakthrough requiring additional treatment. The results provide evidence that tight blood pressure control can protect kidney function in children with chronic kidney disease.
Similar to Influence B Blocker Mch Augustus 2008 1 (20)
betablocker post MI clinical trial , for herat faliure with presered EF
betablocker post MI clinical trial , for herat faliure with presered EF
The New Standard of Care__Leveraging the Benefits of SGLT2 Inhibitors Across ...
The New Standard of Care__Leveraging the Benefits of SGLT2 Inhibitors Across ...
Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..
Newer Approach in management of Angina & CHF: Heart rate modulation and beyond..
HIV Alert- Options for Integrase Inhibitor Therapy Following Recent Drug Appr...
HIV Alert- Options for Integrase Inhibitor Therapy Following Recent Drug Appr...
Trattamento antivirale e controllo della malattia: benefici a lungo termine
Trattamento antivirale e controllo della malattia: benefici a lungo termine
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...
Expert Insights in Selecting a Switch Regimen for Virologically Suppressed HI...
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Simultaneous or Rapid Sequence Initiation of Quadruple Therapy for HFrEF
Medication non-adherence is associated with a broad range of adverse outcomes...
Medication non-adherence is associated with a broad range of adverse outcomes...
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
HF_Managing CHF with beta blcokers in the the era of ARNI.pptx
Influence B Blocker Mch Augustus 2008 1
- 1. Influence of Beta - Blocker Continuation or Withdrawal on Outcomes in Patients Hospitalized With Heart Failure Journal of the American College of Cardiology Vol. 52, No. 3, 2008 Fonarow et al. S. Nadery, MCH 2008
- 2. Vragen en opmerkingen graag bewaren tot aan einde van deze presentatie
- 5. Methods
- 9. Result two
- 15. Result six
- 18. ß-Blocker use and clinical outcomes
- 30. Questions?
Editor's Notes
- Reduced 35 % of total mortality of patient with chronic HF and LVSD